EUCTR2005-004188-50-IT进行中（未招募）不适用
Maintenance of effect of Duloxetine 60 mg Once Daily in patients with Diabetic Peripheral Neuropathic Pain. - ND
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- ELI LILLY
- 入组人数
- 215
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1 Male or female outpatients at least 18 years of age. 2 Present with pain due to bilateral peripheral neuropathy 3 All females must test negative for a pregnancy test at Visit 1. Females of childbearing potential not surgically sterilized and between menarche and 1 year postmenopause must agree to utilize medically acceptable and reliable means of birth control as determined by the investigator during the study and for 1 month following the last dose of the study. Examples of reliable methods include use of oral contraceptives or Depo-Provera Contraceptive Injection sterile medroxyprogesterone acetate suspension, Pharmacia Upjohn , partner with vasectomy, diaphragms with contraceptive jelly, cervical caps with contraceptive jelly, condoms with contraceptive foam, or intrauterine devices. Women who are pregnant or breast-feeding may not participate in the study. 4 Score of 4 on the Brief Pain Inventory BPI 24-hour average pain item at Visit 2. 5 Education level and degree of understanding such that they can communicate intelligibly with the investigator and study coordinator. 6 Judged to be reliable and agree to keep all appointments for clinic visits, tests, and procedures required by the protocol.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •7 Are investigator site personnel directly affiliated with the study, or are immediate family of investigator site personnel directly affiliated with the study. 8 Are employed by Lilly or Boehringer Ingelheim BI 9 Patients who have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry Visit 1 . 10 Patients who have previously completed or withdrawn from this study or any other study investigating duloxetine or have previously been treated with duloxetine. Note Patients who have been previously screened for a duloxetine study other than this study and never received study drug will be eligible for this study if they meet all current entry criteria. 11 Are judged at Visit 1 or Visit 2 to be at suicidal risk by the clinical investigator or as defined by a score of 2 or greater on question 9 of the Beck Depression Inventory-II BDI-II . 12 History of substance abuse or dependence within the past year, excluding nicotine and caffeine. 13 A positive urine drug screen for any substances of abuse. 14 Women who are breast-feeding. 15 Historical exposure to drugs known to cause neuropathy for example, vincristine ,or a history of a medical condition, including pernicious anemia and hypothyroidism, that could have been responsible for neuropathy 16 Pain that cannot be clearly differentiated from or conditions that interfere with the assessment of the diabetic peripheral neuropathy pain. 17 Unstable glycemic control as assessed by a physician investigator and a glycosylated hemoglobin HbA1c 12 before Visit 2. 18 Serious or unstable cardiovascular, hepatic, renal, respiratory, or hematologic illness, symptomatic peripheral vascular disease, or other medical condition or psychiatric conditions that, in the opinion of investigator, would compromise participation or be likely to lead to hospitalization during the course of the study. 19 Acute liver injury such as hepatitis or severe cirrhosis Child-Pugh Class C . 20 Taking any excluded medications that cannot be discontinued at Visit 1. 21 Treatment with a monoamine oxidase inhibitor MAOI within 14 days prior to Visit 2 or the potential need to take during or within 5 days after discontinuation from the study. 22 Treatment with fluoxetine within 30 days prior to Visit 2. 23 Known hypersensitivity to duloxetine or any of the inactive ingredients or patients with frequent or severe allergic reactions to multiple medications. 24 Have uncontrolled or poorly controlled hypertension. 25 Have a seizure disorder. 26 Have uncontrolled narrow-angle glaucoma.
研究者
相似试验
进行中（未招募）
不适用
Maintenance of Effect of Duloxetine 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic PaiEUCTR2005-004188-50-DEEli Lilly and Company215
进行中（未招募）
1 期
Effect of Duloxetine 60 mg to 120 mg Once Daily in Patients with Chronic Low Back Pain - HMEChronic Low Back PainMedDRA version: 8.1Level: LLTClassification code 10003988Term: Back painEUCTR2006-003484-31-FREli Lilly and Company Ltd.230
进行中（未招募）
不适用
Effect of Duloxetine 60 mg to 120 mg Once Daily in Patients with Chronic Low Back Pain - HMEChronic Low Back PainMedDRA version: 8.1Level: LLTClassification code 10003988Term: Back painEUCTR2006-003484-31-DEEli Lilly and Company Ltd.230
进行中（未招募）
不适用
Effect of Duloxetine 60 mg to 120 mg Once Daily in Patients with Chronic Low Back Pain - HMEChronic Low Back PainMedDRA version: 8.1Level: LLTClassification code 10003988Term: Back painEUCTR2006-003484-31-NLEli Lilly and Company Ltd.230
进行中（未招募）
1 期
Efecto de Duloxetina 60 mg, Administrado una Vez al Día, Frente a Placebo, en Pacientes con Lumbalgia CrónicaEffect of Duloxetine 60 mg Once Daily versus Placeboin Patients with Chronic Low Back Pain - HMGCumbalgia CronicaMedDRA version: 9.1Level: LLTClassification code 10024891Term: Low back painEUCTR2008-002248-40-ESilly S.A.400